# Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ihl-42x

> The next catalyst for ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide, sponsored by Incannex Healthcare Inc. (IXHL), is its primary completion, April 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide |
| Codes | IHL-42X |
| Sponsor | Incannex Healthcare Inc. (IXHL) https://sec-api.dev/companies/ixhl/catalysts |
| Indications | [obstructive sleep apnea](https://sec-api.dev/indications/obstructive-sleep-apnea), [Obstructive Sleep Apnea (OSA)](https://sec-api.dev/indications/obstructive-sleep-apnea-osa) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Jan 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-Q (accession 0001213900-25-013783): "In January 2024, we released positive topline results from a completed" https://www.sec.gov/Archives/edgar/data/1873875/000121390025013783/ea0230488-10q_incannex.htm

### January 23, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-01-23, last confirmed 2026-09-25.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-005700): "2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of Obstructive Sleep Apnea (OSA)." https://www.sec.gov/Archives/edgar/data/1873875/000121390025005700/ea022831301ex99-1_incannex.htm
- SEC Form 10-K (accession 0001628280-26-063506): "In January 2025, we announced positive topline results confirming bioavailability of IHL-42X, with PK profiles similar to the reference listed drugs and no serious adverse events reported." https://www.sec.gov/Archives/edgar/data/1873875/000162828026063506/ixhl-20260630.htm
- SEC Form 10-K (accession 0001213900-25-092837): "In January 2025, we announced positive topline results from this trial." https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-013787): "Looking ahead, we are committed to executing our clinical programs and are energized by the upcoming catalysts, including the top-line readout from the U.S. Phase 2 portion of the IHL-42X trial expected in the first half of 2025."" https://www.sec.gov/Archives/edgar/data/1873875/000121390025013787/ea023115301ex99-1_incannex.htm
- SEC Form 8-K (accession 0001213900-25-035636): "Top-line data from the Phase 2 component is expected before the end of the first half of 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025035636/ea0239610-8k_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-028373): "A topline readout from the U.S. Phase 2 portion is anticipated in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/ea023706101ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-009715): "A top-line readout from the U.S. Phase 2 portion is anticipated in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025009715/ea022957601ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-028373): "Topline Phase 2 clinical data expected in the first half 2025" https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/ea023706101ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-005700): "A topline readout from the U.S. Phase 2 portion is anticipated in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025005700/ea022831301ex99-1_incannex.htm

### May 20, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Obstructive Sleep Apnea.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06146101 (RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Incannex Healthcare Ltd." https://clinicaltrials.gov/study/NCT06146101

### Jul 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-05-14, last confirmed 2025-06-24.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-053588): "This eliminates a significant source of dilution and leaves Incannex with a clean capital structure ahead of key milestones, including the upcoming topline data readout from our Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025053588/ea024539601ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-048001): "The agreement comes at a pivotal time for Incannex, as the company approaches the release of top-line data from its Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025048001/ea024346001ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-056901): "The Company expects to report topline Phase 2 data from its U.S. RePOSA study in July 2025, with Phase 3 initiation targeted for later in the year." https://www.sec.gov/Archives/edgar/data/1873875/000121390025056901/ea024665601ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-056901): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025056901/ea024665601ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-055407): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025055407/ea024597501ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-053588): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025053588/ea024539601ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-050327): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/ea024437401ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-048507): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025048507/ea024346601ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-048001): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025048001/ea024346001ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-045651): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025045651/ea024286801ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-044600): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025044600/ea024253501ex99-1_incannex.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-043706): "A topline readout from the U.S. Phase 2 portion is anticipated in July 2025." https://www.sec.gov/Archives/edgar/data/1873875/000121390025043706/ea024232901ex99-1_incannex.htm

### July 23, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: obstructive sleep apnea.
- First seen 2026-07-23, last confirmed 2026-07-23.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-080622): "Australia and NEW YORK, 23 July, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications, is pleased to announce that participant screening has commenced in the Company's DReAMzz Phase 2 dose confirmation study evaluating IHL-42X for the treatment of obstructive sleep apnea ("OSA")." https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea029867401ex99-1.htm

### August 25, 2026: trial start

- Status: completed. Date confidence: exact.
- First seen 2026-08-25, last confirmed 2026-08-25.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-093244): "Incannex Announces First Patient Dosed in DReAMzz" https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea030314001ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-093244): "Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the first patient has been dosed in the DReAMzz Phase" https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea030314001ex99-1.htm

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Obstructive Sleep Apnea (OSA).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07635563 (DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Incannex Healthcare Ltd." https://clinicaltrials.gov/study/NCT07635563

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Obstructive Sleep Apnea (OSA).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07635563 (DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Incannex Healthcare Ltd." https://clinicaltrials.gov/study/NCT07635563

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ihl-42x.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ihl-42x

```bibtex
@misc{secapidev_pdufa_ihl_42x_20261116,
  title        = {Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ihl-42x}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ihl_42x_20261116","title":"Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ihl-42x","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
